Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
about
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyRelevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsPharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteersPharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death.Interactions of Papua New Guinea medicinal plant extracts with antiretroviral therapyInfluence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patientsPopulation pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patientsRapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavirReaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.Reduced indinavir exposure during pregnancy.Traditional Preparations and Methanol Extracts of Medicinal Plants from Papua New Guinea Exhibit Similar Cytochrome P450 InhibitionIndinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.Biotransformation of Cobicistat: Metabolic Pathways and EnzymesPharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.High variability of plasma drug concentrations in dual protease inhibitor regimens.Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes.Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor ELAdherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients.
P2860
Q26771182-FBE62C8B-777E-44DC-AB44-8FA4DFA5877CQ33763177-CB491419-6681-4EE4-90B0-93CEF8ECA2B1Q33981573-E7128C77-24FB-482A-BAFF-FC0120C317AAQ33983047-F4039A55-E50B-4568-B114-0519D23410F9Q34113462-8AF7B4EA-93A1-4A7F-869F-4047E90C68BDQ34253139-766EF937-8F64-4E91-B6DD-6396B8EC95B6Q34340138-015E39D5-8DC9-4CA0-A3C7-DA8549B271D5Q34587582-228DBB87-1A10-45D3-94B9-474FDF40748FQ34677780-DDF247D2-9B49-42C6-8192-988A86F69EFBQ35103600-0CE34CFC-6E57-4B51-88A2-40E50A0C97E5Q35166632-190086D3-A990-425D-94F2-7473E6AA92D5Q35826686-EA0A5C0D-2F24-47BF-9B66-9B3C168E1A13Q35826765-B7A67CF0-F3F3-4751-858B-12121C3FAB27Q36593838-50592395-16B9-4EAA-B879-2586C9A52BBDQ37150887-46073084-AF95-4E98-B608-569F80F4AF10Q37161917-2DCD1D27-36CA-4961-B55F-C0AF2A921D32Q37236043-6FCA7A28-F776-4EC9-916E-264B1229B806Q37433592-C4EC4718-5EB2-463C-BD98-D503F5BE4303Q37598680-A5D3327B-DE67-48FF-B431-B8562CF0631BQ37696729-943623C4-0D3C-4253-A054-86CCF2A4A9D6Q37734814-6E4A5720-319B-44D9-AF28-AB55C5487B1CQ39035831-139DEE6A-6703-4B02-B22F-3EA06D0FD067Q39473480-5FC56247-A2DC-4B19-8CE8-F56D7C4BEF4BQ39682591-F8E432C8-04DE-40EE-A8BC-D9482024172FQ42091235-53971145-4A0B-40CE-A010-1AF8EFF1C1F3Q42284354-CFDCA6A9-AF63-46EF-9160-5CE84BE0DF3DQ43260037-BC5EB3B6-F638-4DF7-8AB1-BB44C0BE6BA9
P2860
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
@ast
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
@en
type
label
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
@ast
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
@en
prefLabel
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
@ast
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
@en
P2093
P2860
P1476
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
@en
P2093
G R Granneman
J M Leonard
L Carothers
P2860
P304
P407
P577
1998-11-01T00:00:00Z